Prof. Jodar (Madrid, Spain)

Additionally there is CAROLINA® in this class of DPP4 inhibitors to assess the cardiovascular safety of linagliptin versus an active comparator. To my knowledge the two really unique cardiovascular outcome trials, CARMELINA® and CAROLINA®, will include different patient population that will span the range of type 2 diabetes covered in this kind of cardiovascular outcome trials. From the early stages of the disease to very advanced people with diabetes with a lot of comorbidities and complications.